Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF18A | Q8NI77 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29608211 | 1.00 | KIF18A (1.00) | KIF18A | |
| Hydrochloric Acid SCHEMBL30141790 | 0.99 | KIF18A (0.98) | KIF18A | |
| Hydrochloric Acid SCHEMBL23925817 | 0.99 | KIF18A (0.98) | KIF18A | |
| SCHEMBL25714193 | 0.95 | KIF18A (0.90) | KIF18A | |
| SCHEMBL22122467 | 0.95 | KIF18A (1.00) | KIF18A | |
| SCHEMBL29607790 | 0.95 | KIF18A (1.00) | KIF18A | |
| SCHEMBL27376387 | 0.92 | KIF18A (0.84) | KIF18A | |
| SCHEMBL24319022 | 0.92 | KIF18A (1.00) | KIF18A | |
| SCHEMBL29608970 | 0.92 | KIF18A (1.00) | KIF18A | |
| SCHEMBL24816992 | 0.91 | KIF18A (0.83) | KIF18A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897855-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2023-06-07 | — | — | EP | claimed |
| US-20220073504-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-03-10 | — | — | US | claimed |
| US-12459932-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20230233565-A1 | A TREATMENT APPROACH INVOLVING KIF18A INHIBITION FOR CHROMOSOMALLY UNSTABLE TUMORS | UNIVERSITY OF VERMONT | 2023-07-27 | — | — | US | disclosed |
| US-20230233565-A1 | A TREATMENT APPROACH INVOLVING KIF18A INHIBITION FOR CHROMOSOMALLY UNSTABLE TUMORS | UNIVERSITY OF VERMONT | 2023-07-27 | — | — | US | disclosed |
| US-20230233565-A1 | A TREATMENT APPROACH INVOLVING KIF18A INHIBITION FOR CHROMOSOMALLY UNSTABLE TUMORS | UNIVERSITY OF VERMONT | 2023-07-27 | — | — | US | disclosed |
| EP-3897855-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3897855-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230151432-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | AMGEN INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151432-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | AMGEN INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151432-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | AMGEN INC. (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4136263-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | Amgen Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20220073504-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-20220073504-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-03-10 | — | — | US | disclosed |
| WO-2021231413-A1 | A TREATMENT APPROACH INVOLVING KIF18A INHIBITION FOR CHROMOSOMALLY UNSTABLE TUMORS | UNIVERSITY OF VERMONT (US) | 2021-11-18 | — | — | WO | disclosed |
| EP-3897855-A1 | KIF18A INHIBITORS | Amgen Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2021211549-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | AMGEN INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2020132651-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073504-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | KIF18A 1/4885 |
| US-20230233565-A1 | A TREATMENT APPROACH INVOLVING KIF18A INHIBITION FOR CHROMOSOMALLY UNSTABLE TUMORS | KIF18A, KIF18B, KIF2C | KIF18A 1/4885 |
| US-20230151432-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | KIF18A, KIF18B, KIF20A | KIF18A 1/4885 |
| US-12459932-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | KIF18A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.